11.48
전일 마감가:
$11.44
열려 있는:
$11.48
하루 거래량:
5.18M
Relative Volume:
0.84
시가총액:
$7.80B
수익:
$125.68M
순이익/손실:
$4.81B
주가수익비율:
2.0319
EPS:
5.65
순현금흐름:
$-781.21M
1주 성능:
-1.29%
1개월 성능:
+0.26%
6개월 성능:
+1.86%
1년 성능:
+4.36%
Roivant Sciences Ltd Stock (ROIV) Company Profile
명칭
Roivant Sciences Ltd
전화
441-295-5950
주소
7TH FLOOR, 50 BROADWAY, LONDON
ROIV을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
ROIV
Roivant Sciences Ltd
|
11.48 | 7.91B | 125.68M | 4.81B | -781.21M | 5.65 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
458.49 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
545.53 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
320.52 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
566.14 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
291.93 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
Roivant Sciences Ltd Stock (ROIV) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-07-10 | 재개 | Goldman | Buy |
2024-02-15 | 개시 | Wolfe Research | Outperform |
2024-01-05 | 개시 | Piper Sandler | Overweight |
2023-12-12 | 개시 | Deutsche Bank | Buy |
2023-10-17 | 개시 | Guggenheim | Buy |
2023-06-08 | 개시 | BofA Securities | Neutral |
2022-10-27 | 개시 | JP Morgan | Overweight |
2022-05-23 | 개시 | SVB Leerink | Outperform |
2022-04-29 | 개시 | Cantor Fitzgerald | Overweight |
2021-12-15 | 개시 | Goldman | Buy |
2021-11-08 | 개시 | H.C. Wainwright | Buy |
2021-10-28 | 개시 | Citigroup | Buy |
2021-10-26 | 개시 | Cowen | Outperform |
2021-10-26 | 개시 | Jefferies | Buy |
2021-10-26 | 개시 | Truist | Buy |
모두보기
Roivant Sciences Ltd 주식(ROIV)의 최신 뉴스
What analysts say about Roivant Sciences Ltd. stockRapid wealth accumulation - Autocar Professional
Roivant Sciences Ltd. Stock Analysis and ForecastExceptional trading performance - PrintWeekIndia
What drives Roivant Sciences Ltd. stock priceFree Investment Community - Autocar Professional
Is Roivant Sciences Ltd. a good long term investmentFree Stock Selection - jammulinksnews.com
(ROIV) Investment Analysis and Advice - news.stocktradersdaily.com
Goldman Sachs resumes Roivant Sciences stock coverage with Buy rating By Investing.com - Investing.com South Africa
Goldman Sachs resumes Roivant Sciences stock coverage with Buy rating - Investing.com India
How to Take Advantage of moves in (ROIV) - news.stocktradersdaily.com
Roivant Sciences: Booming Pipeline Without Product Revenues Creates Valuation Riddle - Seeking Alpha
'Just the beginning': Vivek Ramaswamy breaks record in raising fund for Guv election campaign, $8.5 milli - The Times of India
Roivant Sciences’ president Venker sells $1.15 million in shares - Investing.com India
Roivant Sciences Subsidiary Pulmovant Publishes Positive Phase 1 Data for Inhaled PH Treatment Mosliciguat - Insider Monkey
Roivant Sciences (ROIV): Ramaswamy sells $13 million in shares - Investing.com
HC Wainwright & Co. Reiterates Buy Rating for Roivant Sciences (ROIV) | ROIV Stock News - GuruFocus
Cantor Fitzgerald reiterates overweight rating on Roivant Sciences stock By Investing.com - Investing.com India
H.C. Wainwright reiterates buy rating on Roivant Sciences stock By Investing.com - Investing.com India
Guggenheim maintains buy rating on Roivant Sciences stock amid DM study - Investing.com India
JPMorgan Maintains Positive Outlook on Roivant Sciences (ROIV) | ROIV Stock News - GuruFocus
Roivant (ROIV) Hosts Investor Webinar on Brepocitinib's Role in Dermatomyositis | ROIV Stock News - GuruFocus
Long Term Trading Analysis for (ROIV) - news.stocktradersdaily.com
Roivant (ROIV) Publishes Promising Phase 1 Results for Inhaled M - GuruFocus
Roivant Sciences at Goldman Sachs Conference: Strategic Execution Focus By Investing.com - Investing.com South Africa
Roivant Sciences at Goldman Sachs Conference: Strategic Execution Focus - Investing.com Australia
Roivant and Priovant to Host Investor Video Conference at 1:00 PM ET on Tuesday, June 17 on Brepocitinib and the Unmet Medical Need in Dermatomyositis - Yahoo Finance
Major Shareholder Cashes Out Millions in Roivant Sciences Stock - TipRanks
(ROIV) Trading Advice - news.stocktradersdaily.com
Vivek Ramaswamy’s firm wants to buy biotech companies to bet on bitcoin - MSN
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $324,000 Stock Holdings in Roivant Sciences Ltd. (NASDAQ:ROIV) - Defense World
Roivant Sciences Earnings Call: Balancing Growth and Challenges - MSN
Roivant outlines packed 36-month launch and data cycle with under $5B cash reserve and multi-blockbuster pipeline - MSN
Decoding Roivant Sciences Ltd (ROIV): A Strategic SWOT Insight - GuruFocus
Roivant Sciences Ltd. (NASDAQ:ROIV) Q4 2024 Earnings Call Transcript - Insider Monkey
Roivant Sciences Full Year 2025 Earnings: EPS Beats Expectations, Revenues Lag - simplywall.st
While Wall Street Naps, These 10 Stocks Run Wild - Insider Monkey
Why Roivant Sciences Ltd. (ROIV) Surged On Thursday - Insider Monkey
Roivant Sciences Ltd (ROIV) Q4 2024 Earnings Call Highlights: Strong Financial Position and ... By GuruFocus - Investing.com Canada
Roivant Sciences Reports Progress and Financial Results - TipRanks
IMVT INVESTIGATION ALERT: Investigation Launched into Private Placement Transaction by Immunovant, Inc. and Attorneys Encourage Investors to Contact Law Firm - The Malaysian Reserve
Roivant Sciences Ltd. (ROIV) Reports Q4 Loss, Lags Revenue Estimates - MSN
IMVT INVESTIGATION ALERT: Investigation Launched into Private Placement Transaction by Immunovant, Inc. and Attorneys Encourage Investors to Contact Law Firm – Company AnnouncementFT.com - Financial Times
ROIV Crosses Above Key Moving Average Level - Nasdaq
Roivant Sciences earnings missed by $0.03, revenue fell short of estimates - Investing.com South Africa
Roivant Sciences Q4 2025 Earnings Call Transcript - MarketBeat
Roivant Sciences (ROIV) Stock Jumps Nearly 5%: What’s Fueling This Biotech Rally? - Daily Chhattisgarh News
Roivant Sciences Ltd. Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2025 - marketscreener.com
Transcript : Roivant Sciences Ltd., Q4 2025 Earnings Call, May 29, 2025 - marketscreener.com
Roivant Sciences Ltd reports results for the quarter ended March 31Earnings Summary - TradingView
Tranche Update on Roivant Sciences Ltd.'s Equity Buyback Plan announced on April 2, 2024. - marketscreener.com
Roivant Sciences Ltd. Reports Q4 and FY 2025 Financial Results - TradingView
Roivant Sciences Ltd (ROIV) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):